Evidence map›Paper›PMID 21135372›Full record

ReviewCirculation2010

Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy.

Andrew P Landstrom, Michael J Ackerman

Abstract readCommentReview
In one paragraph

Review in Circulation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Article
  2. Article
  3. Early Cytoskeletal Remodeling Drives Hypertrophic Cardiomyopathy Pathogenesis inJournal of cardiovascular development and disease · 2025
    Article
  4. A New Era in the Management of Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrew P LandstromDepartment of Medicine, Division of Cardiovascular Diseases, and the Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
Michael J Ackerman

Funding

RYANODINE RECEPTORS, Ca2+-TRIGGERED ARRHYTHMIAS AND HCMP01HL094291 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MOSS, RICHARD L · 2009 to 2013
$9.7M
Predoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4M
NHLBI NIH HHS 1P01HL094291NHLBI NIH HHS P01 HL094291NIGMS NIH HHS T32 GM072474
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiomyopathy, HypertrophicGenotypeHumansMutationPredictive Value of TestsPrognosis

Identifiers

PMID21135372
PMCPMC6309993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.